Arcus Biosciences (NYSE:RCUS) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Arcus Biosciences (NYSE:RCUS) from a hold rating to a sell rating in a report released on Saturday.

A number of other equities analysts have also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of Arcus Biosciences in a research report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Monday, April 20th. Citigroup increased their price objective on shares of Arcus Biosciences from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Truist Financial raised shares of Arcus Biosciences to a “strong-buy” rating in a research report on Monday, May 4th. Finally, Wedbush boosted their price target on shares of Arcus Biosciences from $37.00 to $41.00 and gave the stock an “outperform” rating in a research note on Thursday, April 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Arcus Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $33.11.

Arcus Biosciences Stock Performance

NYSE:RCUS opened at $25.37 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.36 and a current ratio of 4.04. The stock has a market capitalization of $3.19 billion, a P/E ratio of -7.98 and a beta of 0.87. The company has a 50 day moving average price of $22.93 and a 200 day moving average price of $22.10. Arcus Biosciences has a fifty-two week low of $7.91 and a fifty-two week high of $28.72.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.10). The company had revenue of $17.00 million for the quarter, compared to analysts’ expectations of $29.49 million. Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The business’s revenue for the quarter was down 39.3% on a year-over-year basis. During the same period in the previous year, the business posted ($1.14) EPS. Equities research analysts forecast that Arcus Biosciences will post -3.55 EPS for the current year.

Institutional Investors Weigh In On Arcus Biosciences

Several institutional investors have recently modified their holdings of RCUS. AQR Capital Management LLC lifted its position in shares of Arcus Biosciences by 253.9% during the 1st quarter. AQR Capital Management LLC now owns 90,954 shares of the company’s stock worth $714,000 after purchasing an additional 65,254 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Arcus Biosciences by 10.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,572 shares of the company’s stock worth $297,000 after purchasing an additional 3,565 shares during the last quarter. Millennium Management LLC lifted its position in shares of Arcus Biosciences by 29.2% during the 1st quarter. Millennium Management LLC now owns 1,194,622 shares of the company’s stock worth $9,378,000 after purchasing an additional 270,253 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Arcus Biosciences by 106.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 914,208 shares of the company’s stock worth $7,177,000 after purchasing an additional 470,755 shares during the last quarter. Finally, Strs Ohio purchased a new stake in shares of Arcus Biosciences during the 1st quarter worth $67,000. 92.89% of the stock is owned by hedge funds and other institutional investors.

Arcus Biosciences News Summary

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Goldman Sachs raised its price target on Arcus Biosciences to $34 from $30 and maintained a buy rating, signaling greater confidence in upside potential.
• Positive Sentiment: HC Wainwright increased several earnings estimates for 2026, 2027, 2029 and 2030, including a higher FY2030 profit forecast, while keeping a buy rating and $32 target.
• Positive Sentiment: Arcus said PEAK-1 enrollment should be complete by year-end 2026 and that its cash runway extends into the second half of 2028, which may ease dilution worries. Article Title
• Neutral Sentiment: HC Wainwright did trim some longer-term estimates, including FY2026, FY2027 and FY2028 EPS, showing that the path to profitability remains challenging despite the higher targets.
• Neutral Sentiment: The company remains deeply unprofitable, and recent earnings results were weaker than expected, so investors are still watching for clinical and operating progress.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.